Mind.Px™ is an innovative precision medicine test developed by Mindera Health, designed to predict the most effective biologic treatment class for individuals with moderate-to-severe plaque psoriasis. Utilizing a minimally invasive dermal biomarker patch, Mind.Px™ captures thousands of RNA transcripts from the skin in just five minutes. This genetic information is then analyzed through next-generation sequencing and machine learning algorithms to provide actionable insights for healthcare providers, enabling personalized treatment plans that improve patient outcomes and reduce healthcare costs.
Key Features and Functionality:
- Minimally Invasive Collection: The dermal biomarker patch allows for rapid and painless extraction of mRNA from the skin, making the process comfortable for patients.
- Advanced Analysis: Employs next-generation sequencing and machine learning-derived classifiers to analyze over 7,000 biomarkers per sample, ensuring precise and reliable results.
- High Predictive Value: Demonstrates a positive predictive value exceeding 91%, effectively guiding clinicians in selecting the appropriate biologic drug class for each patient.
- Clinical Utility: Proven to alter physician prescribing behavior, leading to faster and more effective patient outcomes, as evidenced by randomized, prospective clinical trials.
Primary Value and Problem Solved:
Mind.Px™ addresses the prevalent issue of trial-and-error prescribing in psoriasis treatment by providing personalized, data-driven recommendations for biologic therapy selection. This approach not only enhances patient outcomes by matching individuals with the most effective treatment from the outset but also significantly reduces healthcare expenditures associated with ineffective therapies. By integrating precision medicine into dermatology, Mind.Px™ empowers clinicians to make informed decisions, ultimately improving the quality of care for patients with moderate-to-severe plaque psoriasis.
